Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is an FDA-licensed reference biologic from Teva Women's Health, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2011
Reference approved
Reference product
Not listed Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
Teva Women's Health, Inc.
- Approved
- Mar 16, 2011
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, in chronological order.
Reference approval
Approval date of the reference Adenovirus Type 4 and Type 7 Vaccine, Live, Oral product.
15 yr 5 mo ago
Frequently asked questions
Are there biosimilars approved for Adenovirus Type 4 and Type 7 Vaccine, Live, Oral?
No 351(k) biosimilars or interchangeable biosimilars referencing Adenovirus Type 4 and Type 7 Vaccine, Live, Oral are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.